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Synthesis of 4-bisphosphonocytidyl-2C-methyl-D-erythritol 2, CBPME and 4-bisphosphonocytidyl-2C-methyl-D-erythritol 2-phosphate, CBPME2P. The layers were separated, and the water layer was washed 2  10 mL CH 2 Cl 2 and passed through H + -form DOWEX 50X8-200 resin. Solvents were removed in vacuo to give 845 mg of the crude trimethylbisphosphonic monoacid, which was used without further purification. Crude trimethylbisphosphonic monoacid (830 mg, 3.81 mmol) in 5 mL CH 2 Cl 2 was added dropwise to a solution of Ghosez's reagent (557 mg, 551 L, 4.15 mmol) 3, 4 in 12 mL CH 2 Cl 2 at 40°C, and the mixture was stirred for 5 minutes. The mixture was cooled to 0°C. To this mixture was added Hunig's base (1.34 g, 1.80 mL, 10.4 mmol) followed by 1,3-benzyledene-2C-methyl-D-erythritol 5 (775 mg, 3.46 mmol) and cat. DMAP in one portion. After 5 h, the mixture was quenched with 3 mL sat. NH 4 Cl, diluted with 30 mL EtOAc, and the layers were separated. The water layer was extracted 4  25 mL EtOAc, and the combined organic layers were dried over Na 2 SO 4 , concentrated and purified by flash column chromatography using 5:95 MeOH:EtOAc to give 961 mg (65%) of the desired product as a mixture of diastereomers. ,3S)-3,4-bis(acetyloxy)-1-({[({[(4R,6R)-6-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2 
4-bisphosphonocytidyl-2C-methyl-D-erythritol, CBPME (1).
Compound 14 (30 mg, 0.042 mmol), PhSH (46 mg, 0.42 mmol, 45 L) and Et 3 N (42 mg, 0.42 mmol, 58 L) in 0.40 mL DMF was heated at 70°C for 9 days. Volatiles were removed under reduced pressure, and the resultant crude material was dissolved in 10% MeOH/H 2 O (5 mL). The pH of the solution was adjusted to 2.0 using 1.0 M HCl, and the mixture was stirred for 24 h. The solvents were removed under reduced pressure, and the crude mixture was dissolved in 2 mL of a 2:1:0.5 mixture of MeOH:H 2 O:Et 3 N. After 18 hours, the solvents were removed by rotary evaporation, and the crude mixture was purified by reversed-phase ion-pair HPLC. Reversed phase ion-pair HPLC chromatography. This was accomplished using a Varian Dynamax C 18 250 × 21.4 mm prep column. The column was developed with a linear gradient of 0 to 30% B over 50 minutes at a flow rate of 10 mL/min (where A = 100 mM ammonium acetate buffer, 5 mM tetrabutyl ammonium bisulfate, pH 6.0, and B = acetonitrile containing 5 mM tetrabutyl ammonium bisulfate). Fractions containing the desired compound (λ max = 272 nm, from 17.0 to 20.6 minutes) were combined and concentrated under reduced pressure to remove organic solvent, and the resultant solution was subjected to ion exchange chromatography to convert the product to the ammonium form, using 8 g of NH 4 + -form DOWEX WX8-200 resin. The resultant solution was lyophilized to give 9 mg (39%) of the desired compound as a white powder. + ; Found 520.1097. HPLC analysis: An analytical sample of 1 was analyzed by reversed-phase ion-pair HPLC using an Altima C18 3 , 53  7 mm Rocket  column. The column was developed with a linear gradient of 0 to 100% B at a flow rate of 3 mL/min (where A = 100 mM phosphate buffer, 5 mM tetrabutyl ammonium bisulfate, pH 6.0 and B = 100 mM phosphate buffer, 5 mM tetrabutyl ammonium bisulfate in 30% acetonitrile). The desired compound was >95% pure as shown below.
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HPLC chromatogram of CBPME (1) showing >95% purity. 
4-bisphosphonocytidyl-2C-methyl-D-erythritol 2-phosphate, CBPME2P (2).
A mixture 1 (10 mM), ATP (1 mM), phosphoenol pyruvate (15 mM), MgCl 2 (2.5 mM), pyruvate kinase (3.5 units) and IspE (10 M) in Tris pH 8.0 in a final volume of 744 L was incubated at 37°C for 1 h, and the reaction progress was monitored by HPLC as shown below ( Figure S4 ). After 1 h 10 min, the reaction was quenched with 700 L MeOH, mixed by vortexing and incubated on ice for 10 min. The white precipitate was removed by centrifugation followed by removal of MeOH under reduced pressure. The resultant solution was purified by reversed phase ion-pair HPLC chromatography as described above. Fractions collected at λ max = 272 nm, from 28.7 to 41.4 minutes. Yield: 2.1 mg (43%). + ; Found 600.0769. HPLC analysis: An analytical sample of 2 was analyzed as described for compound 1. The desired compound was >95% pure as shown below. Compound 2 was also co-injected with the IspF substrate, CDPME2P, and exhibits similar chromatographic properties compared to CDPME2P as shown below. Figure S3. IspE-catalyzed phosphorylation of CBPME (1) to form CBPME2P (2) . {[(2S,4R,5S)-5-hydroxy-5-methyl-2-phenyl-1,3-dioxan-4 Table S1 : Rates of CMP formation in the presence of CDPME, CBPME or CBPME2P. Tabulated and normalized rates of CMP formation in the presence of 4-diphosphocytidyl-2C-methyl-D-erythritol 4-phosphate (CDPME, 500 M), 4-bisphosphonocytidyl-2C-methyl-D-erythritol (CBPME, 500 M) and 4-bisphosphonocytidyl-2C-methyl-D-erythritol 2-phosphate (CBPME2P, 500 M). Enzyme reactions were initiated with IspF (0 min pre-incubation) or substrate (30 min pre-incubation), in the presence or absence of additives. 
HPLC chromatogram of CBPME2P (2), showing >95% purity.
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Synthesis of 2C-methyl-D-erythritol 4-bisphosphonic acid (MEBP)
O
